Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas.

Pollino S, Benassi MS, Pazzaglia L, Conti A, Bertani N, Righi A, Piccinni-Leopardi M, Picci P, Perris R.

Histol Histopathol. 2018 Jun;33(6):597-608. doi: 10.14670/HH-11-959. Epub 2018 Jan 3.

PMID:
29297565
2.

Prognostic modeling of oral cancer by gene profiles and clinicopathological co-variables.

Mes SW, Te Beest D, Poli T, Rossi S, Scheckenbach K, van Wieringen WN, Brink A, Bertani N, Lanfranco D, Silini EM, van Diest PJ, Bloemena E, Leemans CR, van de Wiel MA, Brakenhoff RH.

Oncotarget. 2017 Jul 26;8(35):59312-59323. doi: 10.18632/oncotarget.19576. eCollection 2017 Aug 29.

3.

Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.

Farnedi A, Rossi S, Bertani N, Gulli M, Silini EM, Mucignat MT, Poli T, Sesenna E, Lanfranco D, Montebugnoli L, Leonardi E, Marchetti C, Cocchi R, Ambrosini-Spaltro A, Foschini MP, Perris R.

BMC Cancer. 2015 May 3;15:352. doi: 10.1186/s12885-015-1336-4.

4.

Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray.

Bertani N, Malatesta P, Volpi G, Sonego P, Perris R.

J Cell Sci. 2005 Sep 1;118(Pt 17):3925-36. Epub 2005 Aug 9.

5.

Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G, Animati F, Goso C, Maggi CA, Manzini S, Minotti G.

Br J Pharmacol. 2003 Jun;139(3):641-51.

Supplemental Content

Loading ...
Support Center